Cantanhede, Portugal, March 2, 2022 – Exogenus Therapeutics is proud to announce a new research collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles as therapeutic tools for regenerative medicine. This joint effort led by Boehringer Ingelheim’s Research Beyond Borders (RBB) Unit focuses on pre-clinical testing of Exogenus Therapeutics’ lead candidate Exo-101, in various regenerative medicine indications. [Read more…]
Legend Biotech’s CARVYKTI™ Becomes Latest CAR-T Therapy Approved by U.S. FDA
-
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
-
CARVYKTI™ marks the first product approved by a health authority for Legend Biotech
-
Approval is primarily based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with refractory or relapsed multiple myeloma after four or more prior lines of therapy including proteasome inhibitor, immunomodulatory agent and anti-CD38 monoclonal antibody1
Treefrog Therapeutics appoints Scientific Advisory Board to guide the development of proprietary iPS platform & cell therapy pipeline
Bordeaux, France / March 1st, 2022 – TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs. [Read more…]
FDA Grants Orphan Drug Designation to Celularity’s CYNK-101, an NK Cell Therapy for GI Cancers
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need
Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab, and pembrolizumab
5th designation received by Celularity within 12 months from the US FDA
GIOSTAR Chicago Explores Holistic Healing with Chopra Global Chief Medical Officer
Company continues analysis of innovative approaches to healthcare with pioneer in the space
CHICAGO, Feb. 22, 2022 — GIOSTAR Chicago – a leader in regenerative technologies – recently conducted a discussion on holistic healing with Dr. Sheila Patel. The conversation was led by Shelly Sood, GIOSTAR Chicago Founding Partner. Dr. Patel is a board-certified family physician and Chief Medical Officer (CMO) of Chopra Global – “a modern healthcare company positioned at the intersection of science and spirituality,” founded by renowned healthcare expert Dr. Deepak Chopra. The full interview is available on the GIOSTAR Chicago Website, with an accompanying transcript. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 66
- Next Page »
